{
    "clinical_study": {
        "@rank": "131261", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Experimental", 
                "description": "Mesalazine 800 mg orally t.i.d for 3 months"
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "No Intervention", 
                "description": "no treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to obtain an \"in vivo\" confirmation that mesalazine induces the\n      gene expression of \u03bc-protocadherin and other related genes in the colon mucosa, as\n      demonstrated in some \"in vitro\" experiments. ."
        }, 
        "brief_title": "Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an \"in Vivo\" Evaluation of the Molecular Effects on \u03b2-catenin Signaling Pathway.", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Colorectal Cancer", 
            "Diverticular Disease", 
            "Colitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colorectal Neoplasms", 
                "Diverticulum"
            ]
        }, 
        "detailed_description": {
            "textblock": "Pilot Trial, single-blind, parallel group on biopsy specimens of healthy colon mucosa in\n      patients with precancerous lesions of the colon and rectum (adenomas) and concomitant\n      diverticular disease / diverticular colitis treated with mesalazine."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with precancerous colorectal lesions (polypoid or nonpolypoid adenomas) that\n             needs of an endoscopic exam of control after 3 months from the removal of the lesions\n             (determined on the basis of the morphological and histological characteristics of the\n             lesions and of the removal technique)\n\n          -  Clinical diagnosis of diverticular disease or diverticular colitis\n\n          -  Ability and willingness to adhere to study regimen\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Patients under therapy with Aspirin (>100 mg/die) or other FANS\n\n          -  Inflammatory bowel disease (IBD)\n\n          -  Hypersensitivity to Mesalazine.\n\n          -  Pregnant or nursing (lactating) women\n\n          -  Patients who belonging to the category n. 4 of the ASA physical status classification\n             system\n\n          -  contraindications to mesalazine therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02077777", 
            "org_study_id": "MES-CT 01"
        }, 
        "intervention": {
            "arm_group_label": "1", 
            "description": "Mesalazine cpr 800 mg t.i.d. for 3 months", 
            "intervention_name": "Mesalazine", 
            "intervention_type": "Drug", 
            "other_name": [
                "5-aminosalicylic acid", 
                "5-ASA", 
                "Pentacol"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Aminosalicylic Acid", 
                "Mesalamine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "mesalazine", 
            "colon", 
            "cancer", 
            "diverticular", 
            "disease"
        ], 
        "lastchanged_date": "February 28, 2014", 
        "location": {
            "contact": {
                "email": "f.buffoli@ospedale.cremona.it", 
                "last_name": "Federico Buffoli, Doctor", 
                "phone": "0036 0372 405250"
            }, 
            "facility": {
                "address": {
                    "city": "Cremona", 
                    "country": "Italy", 
                    "zip": "26100"
                }, 
                "name": "Istituti Ospitalieri di Cremona"
            }, 
            "investigator": {
                "last_name": "Federico Buffoli, Doctor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Azione Chemiopreventiva Della Mesalazina Sul Cancro Del Colon-retto: Studio Pilota Per la Valutazione Degli Effetti Molecolari \"in Vivo\" Sulla Via di Segnalazione Proliferativa Della \u03b2-catenina (Official Title in Italian Language)", 
        "overall_official": {
            "affiliation": "Istituti Ospitalieri di Cremona", 
            "last_name": "Federico Buffoli, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: National Monitoring Centre for Clinical Trials - Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Molecular analysis (quantitative RT-PCR) of gene expression levels of \u03bc-protocadherin, protocadherin 19, protocadherin 24, cadherin E, TCF7L2, TCF4, c-myc, Cyclin D1, p21waf1, VEGF, CD44, Met, KLF4 e CEBP-\u03b1 and comparison of the levels assessed at the end of the treatment period with the baseline.", 
            "measure": "Molecular analysis of gene expression levels of \u03bc-protocadherin and other related proteins", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "reference": [
            {
                "PMID": "19785626", 
                "citation": "Parenti S, Ferrarini F, Zini R, Montanari M, Losi L, Canovi B, Ferrari S, Grande A. Mesalazine inhibits the beta-catenin signalling pathway acting through the upregulation of mu-protocadherin gene in colo-rectal cancer cells. Aliment Pharmacol Ther. 2010 Jan;31(1):108-19. doi: 10.1111/j.1365-2036.2009.04149.x. Epub ."
            }, 
            {
                "PMID": "21315419", 
                "citation": "Losi L, Parenti S, Ferrarini F, Rivasi F, Gavioli M, Natalini G, Ferrari S, Grande A. Down-regulation of \u03bc-protocadherin expression is a common event in colorectal carcinogenesis. Hum Pathol. 2011 Jul;42(7):960-71. doi: 10.1016/j.humpath.2010.10.009. Epub 2011 Mar 2."
            }, 
            {
                "PMID": "19879273", 
                "citation": "Brown JB, Lee G, Managlia E, Grimm GR, Dirisina R, Goretsky T, Cheresh P, Blatner NR, Khazaie K, Yang GY, Li L, Barrett TA. Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology. 2010 Feb;138(2):595-605, 605.e1-3. doi: 10.1053/j.gastro.2009.10.038. Epub 2009 Oct 29."
            }, 
            {
                "PMID": "15929768", 
                "citation": "Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005 Jun;100(6):1345-53."
            }, 
            {
                "PMID": "19891667", 
                "citation": "Lyakhovich A, Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther. 2010 Jan 15;31(2):202-9. doi: 10.1111/j.1365-2036.2009.04195.x. Epub 2009 Nov 5. Review."
            }, 
            {
                "PMID": "19479711", 
                "citation": "Gushima M, Hirahashi M, Matsumoto T, Fujita K, Fujisawa R, Mizumoto K, Nakabeppu Y, Iida M, Yao T, Tsuneyoshi M. Altered expression of MUTYH and an increase in 8-hydroxydeoxyguanosine are early events in ulcerative colitis-associated carcinogenesis. J Pathol. 2009 Sep;219(1):77-86. doi: 10.1002/path.2570."
            }, 
            {
                "PMID": "20534734", 
                "citation": "Obtulowicz T, Swoboda M, Speina E, Gackowski D, Rozalski R, Siomek A, Janik J, Janowska B, Ciesla JM, Jawien A, Banaszkiewicz Z, Guz J, Dziaman T, Szpila A, Olinski R, Tudek B. Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients. Mutagenesis. 2010 Sep;25(5):463-71. doi: 10.1093/mutage/geq028. Epub 2010 Jun 9."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02077777"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "These parameters will be examined using molecular analysis of the oxidation and depurination levels of the DNA and chromatographic analysis of the intra-mucosal concentration of 5-Acetylsalicylic acid, in biopsies of normal mucosa of the colon taken before and after the treatment of patients with 5-Acetylsalicylic acid:\nquantification of the percentage of cells expressing the following proteins by immunohistochemical analysis: \u03bc-protocadherin, Ki-67, Caspase-3 and Histone H2AX\u03b3;\nquantification of number of AP sites per 100000 DNA bp\nquantification of nanograms di 8-OhdG (8-hydroxyguanine) per micrograms of DNA", 
            "measure": "Evaluation of protein expression level of \u03bc-protocadherin, Ki-67, Caspase-3 and Histone H2AX\u03b3, evaluation of DNA oxidative damage and intra-mucosal concentration of 5-Acetylsalicylic acid", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "SOFAR S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "SOFAR S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}